Therapeutic approach guided by genetic alteration: Use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression

References

• Maroja Silvino MC, Venchiarutti Moniz CM, Munhoz Piotto GH, Siqueira S, Galapo Kann A, Dzik C. Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil. Rare Tumors 2013; 5:e44; PMID:24179656
   PubMedGoogle Scholar
• Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V, Dutcher JP, Ghavamian R. Renal medullary carcinoma: the Bronx experience. Urology 2007; 70:878-82; PMID:18068443; http://dx.doi.org/10.1016/j.urology.2007.06.1124
   PubMed Web of Science ®Google Scholar
• Simpson L, He X, Pins M, Huang X, Campbell SC, Yang XJ, Perlman EJ, Bergan RC. Renal medullary carcinoma and ABL gene amplification. J Urol 2005; 173:1883-8; PMID:15879768; http://dx.doi.org/10.1097/01.ju.0000158448.56888.09
   PubMed Web of Science ®Google Scholar
• Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol 2013; 37:368-74; PMID:23348212; http://dx.doi.org/10.1097/PAS.0b013e3182770406
   PubMed Web of Science ®Google Scholar
• Calderaro J, Moroch J, Pierron G, Pedeutour F, Grison C, Maille P, Soyeux P, de la Taille A, Couturier J, Vieillefond A, et al. SMARCB1INI1 inactivation in renal medullary carcinoma. Histopathology 2012; 61:428-35; PMID:22686875; http://dx.doi.org/10.1111/j.1365-2559.2012.04228.x
   PubMed Web of Science ®Google Scholar
• Davis CJ, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995; 19:1-11; PMID:7528470; http://dx.doi.org/10.1097/00000478-199501000-00001
   PubMed Web of Science ®Google Scholar
• O’Donnell PH, Jensen A, Posadas EM, Bridge JA, Yeldandi AV, Yang XJ, Stadler WM, Al-Ahmadie H. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol 2010; 7:110-4; http://dx.doi.org/10.1038/nrurol.2009.255
   PubMed Web of Science ®Google Scholar
• Gupta R, Billis A, Shah RB, Moch H, Osunkoya AO, Jochum W, Hes O, Bacchi CE, de Castro MG, Hansel DE, et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol 2012; 36:1265-78; PMID:22895263; http://dx.doi.org/10.1097/PAS.0b013e3182635954
   PubMed Web of Science ®Google Scholar
• Avery RA, Harris JE, Davis CJ, Borgaonkar DS, Byrd JC, Weiss RB. Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor. Cancer 1996; 78:128-32; PMID:8646708; http://dx.doi.org/10.1002/(SICI)1097-0142(19960701)78:1%3c128::AID-CNCR18%3e3.0.CO;2-1
   PubMed Web of Science ®Google Scholar
• Bell MD. Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma. Pediat Blood Cancer 2006; 47:228; PMID:16514612; http://dx.doi.org/10.1002/pbc.20780
   PubMed Web of Science ®Google Scholar
• Gangireddy V, Liles GB, Sostre GD, Coleman T. Response of metastatic renal medullary carcinoma to carboplatinum and Paclitaxel chemotherapy. Clin Genitourin Cancer 2012; 10:134-9; PMID:22409864; http://dx.doi.org/10.1016/j.clgc.2012.01.003
   PubMed Web of Science ®Google Scholar
• Rathmell WK, Monk JP. High-dose-intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review. Urology 2008; 72:659-63; PMID:18649931; http://dx.doi.org/10.1016/j.urology.2008.05.009
   PubMed Web of Science ®Google Scholar
• Watanabe IC, Billis A, Guimaraes MS, Alvarenga M, de Matos AC, Cardinalli IA, Filippi RZ, de Castro MG, Suzigan S. Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol: Off J U S Can Acad Pathol, Inc 2007; 20:914-20; PMID:17643096; http://dx.doi.org/10.1038/modpathol.3800934
   PubMed Web of Science ®Google Scholar
• Anne M, Sammartino D, Chaudhary S, Bhuiya T, BM. Renal medullary carcinoma masquerading as bilateral breast carcinoma category: case report. Vol 4. 3 ed. World J Oncol 2013; 169-72.
   Google Scholar
• Noguera-Irizarry WG, Hibshoosh H, Papadopoulos KP. Renal medullary carcinoma: case report and review of the literature. Am J Clin Oncol 2003; 26:489-92; PMID:14528077; http://dx.doi.org/10.1097/01.coc.0000037663.61643.5A
   PubMed Web of Science ®Google Scholar
• Assad L, Resetkova E, Oliveira VL, Sun W, Stewart JM, Katz RL, Caraway NP. Cytologic features of renal medullary carcinoma. Cancer 2005; 105:28-34; PMID:15593260; http://dx.doi.org/10.1002/cncr.20764
   PubMed Web of Science ®Google Scholar
• Schaeffer EM, Guzzo TJ, Furge KA, Netto G, Westphal M, Dykema K, Yang X, Zhou M, Teh BT, Pavlovich CP. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int 2010; 106:62-5; PMID:20002663; http://dx.doi.org/10.1111/j.1464-410X.2009.09139.x
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Spevak M, Mack AK, Arceci RJ, Small D, Loeb DM. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediat Blood Cancer 2005; 44:407-11; PMID:15602719; http://dx.doi.org/10.1002/pbc.20292
   PubMed Web of Science ®Google Scholar
• Swartz MA, Karth J, Schneider DT, Rodriguez R, Beckwith JB, Perlman EJ. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology 2002; 60:1083-9; PMID:12475675; http://dx.doi.org/10.1016/S0090-4295(02)02154-4
   PubMed Web of Science ®Google Scholar
• Yang XJ, Sugimura J, Tretiakova MS, Furge K, Zagaja G, Sokoloff M, Pins M, Bergan R, Grignon DJ, Stadler WM, et al. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer 2004; 100:976-85; PMID:14983493; http://dx.doi.org/10.1002/cncr.20049
   PubMed Web of Science ®Google Scholar
• Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M, Bridge JA. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol: Off J U S Can Acad Pathol, Inc 2011; 24:430-42; PMID:21076462; http://dx.doi.org/10.1038/modpathol.2010.213
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Lilleberg SL, Monzon FA, Koul MS, Bridge JA, Knezetic J, Legendre B, Sharma P, McCue PA. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes. Hum Pathol 2011; 42:1979-88; PMID:21733559; http://dx.doi.org/10.1016/j.humpath.2011.02.026
   PubMed Web of Science ®Google Scholar
• Jianjun Gao, Hui Yao, Xiaoping Su, Priya Rao, Padmanee Sharma, Jose A. Karam, Christopher G. Wood, Tannir NM. Molecular characterization of renal medullary carcinoma (RMC). J Clin Oncol 32:5s, 2014 (suppl; abstr 4586); http://dx.doi.org/10.1200/JCO.2013.49.4757
   Google Scholar
• Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bartschi D, Droge C, Gautschi O, Borner M, Fechter E, Stenner F, et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 0808). Eur Urol 2013; 64:150-8; PMID:23582881; http://dx.doi.org/10.1016/j.eururo.2013.03.040
   PubMed Web of Science ®Google Scholar